---
title: "002020.SZ (002020.SZ) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/002020.SZ/news.md"
symbol: "002020.SZ"
name: "002020.SZ"
parent: "https://longbridge.com/zh-HK/quote/002020.SZ.md"
datetime: "2026-03-17T06:55:41.251Z"
locales:
  - [en](https://longbridge.com/en/quote/002020.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002020.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002020.SZ/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/002020.SZ/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/002020.SZ/news.md)


# 002020.SZ (002020.SZ) — 相關新聞

### [JINGXIN: The external authorization work for the new lipid-lowering drug LP(a) JX2201 is progressing](https://longbridge.com/zh-HK/news/278050942.md)
*2026-03-06T07:44:15.000Z*
> JINGXIN stated on the interactive platform that the external authorization work for the new lipid-lowering drug LP(a) JX

### ["AIDS Resistance" leader Aidea Pharma plans to raise 1.277 billion through a private placement to "supplement blood," the company has reported losses for 5 consecutive years](https://longbridge.com/zh-HK/news/277644946.md)
*2026-03-03T14:31:18.000Z*
> Jiangsu Aidea Pharma Group Co., Ltd. plans to raise no more than 1.277 billion yuan by issuing shares to specific target

### [[IPO Frontline] A veteran of A-shares in 2022 challenges the Hong Kong stock market: The innovative drug gamble of JINGXIN](https://longbridge.com/zh-HK/news/277459350.md)
*2026-03-02T11:46:10.000Z*
> JINGXIN recently applied for listing on the Hong Kong Stock Exchange. If successful, it will become a dual-listed biotec

### [Behind JINGXIN's IPO: A Reassessment Battle of a "Cash Flow Pharmaceutical Company"](https://longbridge.com/zh-HK/news/275883754.md)
*2026-02-13T10:08:18.000Z*
> JINGXIN is facing a reassessment of its identity in its IPO on the Hong Kong Stock Exchange. Despite the company's stron

### [JINGXIN Pharmaceuticals rushes to the Hong Kong stock market: 10 months revenue of 3.3 billion, profit of 629 million, just declared a dividend of 285 million](https://longbridge.com/zh-HK/news/275702557.md)
*2026-02-12T04:36:52.000Z*
> JINGXIN plans to list on the Hong Kong Stock Exchange, having already been listed on the A-share market with a market ca

### [JINGXIN submitted an application for the issuance and listing of H shares](https://longbridge.com/zh-HK/news/275676428.md)
*2026-02-12T00:12:02.000Z*
> JINGXIN has submitted an application for the issuance and listing of H shares to the Hong Kong Stock Exchange on Februar

### [New Stock News | JINGXIN submitted an application to the Hong Kong Stock Exchange, focusing on central nervous system, cardiovascular, and cerebrovascular diseases](https://longbridge.com/zh-HK/news/275672731.md)
*2026-02-11T23:28:05.000Z*
> Zhejiang JINGXIN Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange and has be

### [](https://longbridge.com/zh-HK/news/275622947.md)
*2026-02-11T14:35:23.000Z*
> According to Hong Kong Stock Exchange documents: Zhejiang JINGXIN Pharmaceutical Co., Ltd. submitted a listing applicati

### [JINGXIN: The first holder meeting of the fourth employee stock ownership plan passed multiple proposals](https://longbridge.com/zh-HK/news/273355297.md)
*2026-01-22T10:12:58.000Z*
> JINGXIN held the first holder meeting of the fourth employee stock ownership plan on January 21, 2026, with 215 attendee